Ocugen (OCGN) Change in Cash (2014 - 2026)
Ocugen's (OCGN) quarterly Change in Cash came in at $13.3 million in Q1 2026, up 164.15% YoY from $5.0 million in Q1 2025, and up 194.96% on a QoQ basis from -$14.0 million in Q4 2025.
Analysis
Ocugen (OCGN) Change in Cash (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Change in Cash data on file, last reported at $13.3 million in Q1 2026.
- Quarterly Change in Cash rose 164.15% year-over-year to $13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.9 million (down 150.59% YoY) and the FY2025 annual result came in at -$39.9 million, down 306.28% from the prior year.
- Change in Cash climbed to $13.3 million in Q1 2026, from -$14.0 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $34.8 million in Q1 2022 to a low of -$24.0 million in Q4 2022.
- A 5-year average of -$3.7 million and a median of -$10.8 million in 2025 frame the typical range for Change in Cash.
- The widest YoY moves for Change in Cash: up 241.42% in 2024, down 547.43% in 2024.
- Tracing OCGN's Change in Cash over 5 years: stood at -$24.0 million in 2022, then soared by 41.7% to -$14.0 million in 2023, then surged by 241.42% to $19.8 million in 2024, then sank by 170.59% to -$14.0 million in 2025, then jumped by 194.96% to $13.3 million in 2026.
- The last three Change in Cash figures came in at $13.3 million (Q1 2026), -$14.0 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -185.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 427.25 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | 68.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 68.20 Mn |
| Mar 31, 2026 | 13.29 Mn |
| Dec 31, 2025 | -13.99 Mn |
| Sep 30, 2025 | 5.55 Mn |
| Jun 30, 2025 | -10.79 Mn |
| Mar 31, 2025 | -20.71 Mn |
| Dec 31, 2024 | 19.82 Mn |
| Sep 30, 2024 | 23.00 Mn |
| Jun 30, 2024 | -10.38 Mn |
| Mar 31, 2024 | -13.09 Mn |
| Dec 31, 2023 | -14.02 Mn |
| Sep 30, 2023 | -17.10 Mn |
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | -9.30 Mn |
| Dec 31, 2022 | -24.04 Mn |
| Sep 30, 2022 | -13.40 Mn |
| Jun 30, 2022 | -14.92 Mn |
| Mar 31, 2022 | 34.81 Mn |
| Dec 31, 2021 | -12.39 Mn |
| Sep 30, 2021 | -8.29 Mn |